CAM
FHTX icon

Cormorant Asset Management’s Foghorn Therapeutics FHTX Stock Holding History

Cormorant Asset Management’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,000,000
Closed -$13.2M – 112
2021
Q1 		$13.2M Hold
1,000,000
– – 0.29% 64
2020
Q4 		$20.3M Buy
+1,000,000
New +$19.2M 0.48% 48

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Cormorant Asset Management's FHTX Position: Q2 2021 in Review

Cormorant Asset Management sold out of Foghorn Therapeutics (FHTX) in Q2 2021, closing a stake of 1,000,000 shares — an estimated $13.2M sold.

Cormorant Asset Management first reported a position in FHTX in Q4 2020 and held it in 2 quarters. The position peaked at $20.3M in Q4 2020. 39 funds tracked by Wall St. Rank hold FHTX as of Q2 2021.

  • Cormorant Asset Management reported no remaining Foghorn Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Cormorant Asset Management sold 1,000,000 Foghorn Therapeutics shares in Q2 2021, an estimated $13.2M.
  • Cormorant Asset Management first reported a position in Foghorn Therapeutics in Q4 2020 and held it in 2 quarters.
  • Cormorant Asset Management's Foghorn Therapeutics position peaked at $20.3M in Q4 2020.
  • 39 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2021.

Based on Cormorant Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.